Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy. Show more

Location: | Website: www.vallon-pharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

931.3M

52 Wk Range

$N/A - $N/A

Previous Close

$1.85

Open

$1.84

Volume

191,165

Day Range

$1.73 - $1.87

Enterprise Value

0.00

Cash

159.3M

Avg Qtr Burn

N/A

Insider Ownership

23.42%

Institutional Own.

13.28%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date